Takeda’s Weber expects expansion of precompetitive space, new alliance formats coming out of COVID-19: a BioCentury audio interview
Weber points to plasma alliance for hyperimmune globulin, AMR fund as templates for collaboration, preparedness
Takeda President and CEO Christophe Weber says COVID-19 could permanently change the way drugs are developed by leading companies to expand the precompetitive space and enter into new kinds of alliances. He also thinks it’s essential to maintain momentum for COVID-19 therapies even after vaccines arrive, and that collaborative platforms can help to prepare for the next pandemic.
In a BioCentury Back to School audio interview, Weber described some of the collaborations Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) has participated in, and how he thinks these can and should contribute to ongoing initiatives to beat COVID-19 and learn from it. The interview is part of a series of conversations with key industry leaders for BioCentury’s Back to School package (see Cover Story: “Back to School 2020”)...